Looks back at colorectal cancer patients treated with an immune drug plus standard therapy
Compares survival in colorectal cancer patients with and without an immune-modulating drug.
Plain-language title generated from the registry record
Registry title: Clinical Outcomes of Treatment With Immunomodulator Plus Cancer Therapies for Patients With Colorectal Cancer
Key facts
- Where
- Taichung, TaiwanSee the 2 sites
Where in Taiwan
- Chung Shan Medical University HospitalTaichung, TaiwanNot yet recruiting
- Taichung Veterans General HospitalTaichung, TaiwanTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Taichung Veterans General Hospital
- Trial code
- NCT06557668
- Record updated
- 29 January 2026
- Original description
This study aims to evaluate the survival and treatment outcomes among colorectal cancer patients undergoing anti-cancer treatment, both with and without an immunomodulator.Read full original descriptionShow less
Clinical Outcomes of Treatment With Immunomodulator Plus Standard Anti-cancer Therapies for Patients With Colorectal Cancer: A Retrospective Study
This study aims to evaluate the survival and treatment outcomes among colorectal cancer patients undergoing anti-cancer treatment, both with and without an immunomodulator.
Inclusion: Aged 20 years and older; Patients who have been given a diagnosis of colorectal cancer; Patients had previously initiated anti-cancer therapies between January 1, 2020, and Apr 30, 2024.
Exclusion: None.